Blood Cancers

Researchers identified five traits that may increase a person’s chance of experiencing polycythemia vera progression.

Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia had better MRD statuses after receiving Iclusig, compared with Gleevec.

Contrary to past research, blood cancer survivors may have safe and successful pregnancies up to 10 years after an allogeneic stem cell transplant.

Although MDS didn’t leave physical scars, the invisible ones, like side effects from treatment, are ones that linger.

More frequent immunoglobulin G testing was associated with a decreased risk of severe infections in patients with CLL and non-Hodgkin lymphoma.

For patients with MDS who benefit from delaying transplants, it’s important to take care of their health while savoring their time before transplant.

From Don Omar announcing being cancer free to “General Hospital” star John York talking about treatment for his two cancers, here’s what’s going on in the oncology space this week.

As a cancer survivor, I realize that life doesn’t always go the way we think it will, but it doesn’t erase the guilt.

Approximately half of the patients with MDS who responded to treatment with Rytelo went a year without needing a blood transfusion, one expert explained.

The Food and Drug Administration has approved Rytelo to treat certain patients with low- to intermediate-1 risk MDS with transfusion-dependent anemia.

Patients with myelodysplastic syndromes tended to have longer periods of time without needing a red blood cell transfusion when treated with Reblozyl.

The safety profile of 200 milligrams and 300 milligrams of oral Ongureg were similar in patients with lower- to intermediate-risk MDS.

As a cancer survivor, I’m pleading for more research on cancer related fatigue.

When possible, immune checkpoint inhibitors should be avoided in pregnant women with cancer due to lung inflammation and possible miscarriage, researchers found.

Pelabresib plus Jakafi led to a reduction in spleen size and was tolerable in patients with myelofibrosis, according to data from MANIFEST-2.

I was surprised that COVID-19 taught me how to cope with the daily annoyances of cancer.

Childbirth rates have been reduced by 22% in women with MPNs, compared with women without MPNs, researchers found.

The Food and Drug Administration approved multiple new therapies for blood cancer over the last few months.

The novel treatment elritercept received a Fast Track designation from the FDA to treat anemia in patients with MDS.

An FDA committee voted that the benefits of Carvykti outweigh the risks for myeloma treatment, though concerns about secondary malignancies remain.

Patients taking Tibsovo to treat MDS or AML may want to discuss the appropriate medications to treat and prevent infections, an expert said.

The Oncologic Drug Advisory Committee voted that the benefits of imetelstat outweigh the risks for transfusion-dependent myelodysplastic syndrome and anemia.

Attending follow-up appointments as blood cancer survivors can help prevent more dangerous outcomes, including secondary cancers, an expert told CURE®.

An oral suspension formula of Imbruvica received the green light from the Food and Drug Administration to be used in all approved indications.

The first patient has been enrolled in a clinical trial evaluating a reduced dose of post-transplant immunosuppressive chemotherapy cyclophosphamide for patients with blood cancers.

Orca-T outperformed post-transplant cyclophosphamide when it came to relapse-free survival and overall survival in patients with blood cancer who underwent a stem cell transplantation from a matched unrelated donor.

Jakafi plus Rezurock showed promise in treating graft-versus-host disease in patients who underwent undergone allogeneic hematopoietic cell transplantation.

Treatment with rusfertide led to a decrease in the need for blood draws and decreased levels of red blood cells in patients with polycythemia vera.

Most patients with relapsed or refractory multiple myeloma responded to treatment with the CAR-T cell therapy, Carvykti, according to a small study.

A cancer survivor described the agony of making a life-or-death decision.